Before joining PepGen, Dr. Kasraian served at bluebird bio, where he was instrumental in the approval and launch of three gene therapy products: SKYSONA™, ZYNTEGLO™, and LYFGENIA™.

PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological ...

Kasra’s background advancing therapies for rare genetic disorders, along with his ability to navigate manufacturing and regulatory landscapes, will be instrumental as we ... Dr. Kasraian joins PepGen ...

In 1912, WC Handy published “Memphis Blues,” which, ironically, is not a blues song, but an instrumental cakewalk ... and the antecedent of BB’s sound. Bluebird, the Columbia subsidiary ...

MACON, Ga., May 21, 2025--The Blue Bird School Bus Foundation, charitable arm of iconic school bus manufacturer Blue Bird Corporation (Nasdaq: BLBD), continues to advance the education ...

Nature will provide it very soon. Today is our first official day of rainy season," he said. "And it's a bluebird day, not a single cloud in the sky. But it's coming, rain is coming." ...

ALLENTOWN, Pa. – President Donald Trump supporters and Americans for Prosperity (AFP) protesters lined the streets outside Democrat Rep. Ro Khanna's town hall in the battleground state of ...

You have reached your maximum number of articles. Log in or create an account FREE of charge to continue reading. President Donald Trump’s "one big, beautiful bill" survived a key hurdle in the ...

The Jacksonville Aviation Authority ended the mystery over the identity of "Project Bluebird" by revealing Otto Aviation is the company that could build Jacksonville's first passenger plane ...

The String Cheese Incident opened its spring tour with a pair of mid-week Incidents in Wilmington before linking up with The ...

BRASILIA (Reuters) -Brazil's poultry industry is reeling from the country's first bird flu outbreak on a commercial farm, but officials hope China and other major consumers will soon loosen ...

It’s back to the drawing board for bluebird bio and its discussions with NICE, which has rejected its beta thalassaemia gene therapy Zynteglo for regular NHS use in first draft guidance.